Quiet

Quick links to important sections

Quiet

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quiet

Property Description
Active ingredient Quetiapine fumarate
Form Oral tablet (Immediate-release & extended-release)
Pharmacological class Atypical Antipsychotic (Second-Generation)
Common use Stabilizing mood and thought processes
Origin Synthetic compound (Dibenzothiazepine derivative)

What is Quiet and What Type of Medicine is It?

Quiet is a synthetic psychotropic agent containing the active ingredient Quetiapine fumarate, formally classified as an atypical antipsychotic, or Second-Generation Antipsychotic (SGA). This medicine belongs to the dibenzothiazepine derivative chemical class. Quetiapine is a prescription medication that acts on the central nervous system. Its differentiation from older treatments is clinically recognized due to its specific receptor binding profile.

This classification is significant because Quetiapine’s mechanism is defined by a dual action. It functions as a serotonin-dopamine antagonist (SDA), meaning it modulates signals from both dopamine and serotonin, which is key to its role as a neuro-stabilizing agent. Quetiapine's dual interaction with these major neurotransmitter systems helps to restore balance in brain chemistry, which is the cornerstone of its intended clinical effect.

Composition and Available Forms of Quetiapine

Quiet is a single-ingredient product, containing only Quetiapine fumarate along with necessary solid pharmaceutical excipients for delivery via the oral route. It is supplied exclusively as an oral tablet.

The preparation is offered in both an immediate-release tablet, designed for rapid absorption, and an extended-release tablet. This extended-release form is specifically engineered with pharmaceutical technology to release the active compound gradually, ensuring a steady presence of the medicine in the body over a longer duration. This variability in delivery is a key feature distinguishing the formulation options.

How Quetiapine Generally Supports Brain Function

The general purpose of Quetiapine is to support the stabilization of emotional states and the normalization of thought patterns in individuals experiencing certain imbalances. This is achieved through its SDA action, which regulates the flow of information across vital neural pathways. By tempering specific signals at dopamine and serotonin receptors, Quetiapine helps establish a more regulated chemical environment in the brain, supporting a more stable and functional mental state.

Regulatory References

  1. NIH Review
  2. NIH

What side effects are possible with Quiet?

The regulatory safety profile of Quetiapine fumarate is structured by adverse reactions classified according to frequency and affected body systems. The most frequently documented effects, classified as Very Common, are disturbances in the Nervous System such as somnolence and dizziness, along with significant Metabolic changes including dry mouth and weight gain. Other commonly reported findings include orthostatic hypotension, tachycardia, and abnormalities in liver function tests.

System-Organ-Class and Serious Risks

Adverse events are documented across several System-Organ Classes, including the Metabolism and Nutrition Disorders (e.g., dyslipidemia, hyperglycemia) and Blood and Lymphatic System Disorders (e.g., leukopenia). The official label explicitly lists several Serious Adverse Reactions, which include the risk of Neuroleptic Malignant Syndrome (NMS), life-threatening Agranulocytosis, and severe Hyperglycemia that can lead to ketoacidosis. The risk of Tardive Dyskinesia, a syndrome of involuntary movements, is also a serious safety consideration associated with long-term use.

Population and Duration Safety Patterns

Specific safety considerations are mandated for distinct patient groups. There is an increased regulatory warning for Suicidal Thoughts and Behaviors in children, adolescents, and young adults (le 24 years). Furthermore, the official label documents specific high risks for elderly patients with dementia-related psychosis, including increased mortality and cerebrovascular adverse reactions. Effects like Orthostatic Hypotension are noted as being most likely during the initial dose titration period, linking the risk profile directly to the duration of treatment. The medicine is contraindicated for known hypersensitivity to any component.

Overdose and Emergency Response

Overdose Scope

Property Content (Strictly Label-Derived)
Documented Overdose Presentations Symptoms officially listed include drowsiness, somnolence, tachycardia (fast heart rate), hypotension (low blood pressure), dizziness, and slurred speech.
Physiological Systems Affected The Central Nervous System (CNS) and Cardiovascular System are the primary systems affected. Severe manifestations include respiratory depression and QTc interval prolongation (cardiac risk).
Dose-related or Exposure-related Factors Patients who have ingested the extended-release formulation may require prolonged monitoring due to the potential for delayed onset of severe effects.
Population-specific Overdose Notes The regulatory profile highlights an increased risk of severe outcomes for elderly patients and individuals with pre-existing cardiovascular disease.
Emergency-response Statements Management is defined as symptomatic and supportive treatment, including establishing a clear airway and continuous cardiovascular monitoring.
When immediate medical help is required Immediate medical attention must be sought if overdose is suspected, especially if symptoms include collapse, seizures, trouble breathing, or inability to be awakened.

Overdose Classifications (High-Level)

Classification Content (Strictly Label-Derived)
Severity Classification Official documents report severe outcomes including coma and death.
Overdose-Context Constraints The regulatory label explicitly states that no specific antidote is known. The use of epinephrine and dopamine should be avoided for treating hypotension due to potential exacerbation.

Official Overdose Statements

Official documentation confirms that overdose presents with signs of CNS depression and cardiovascular instability. Life-threatening consequences include coma, death, and severe cardiac events. Regulators mandate seeking immediate medical attention and require management to be symptomatic and supportive, focusing on continuous observation and maintenance of vital functions.

Therapeutic Uses of Quiet

The core therapeutic value of Quetiapine is its ability to provide symptomatic support across therapeutic domains for conditions characterized by significant instability in mood, emotion, and thought processes. It helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability.

Quetiapine is used to treat Schizophrenia, Bipolar Disorder (including manic and depressive episodes), and is prescribed as adjunctive therapy with antidepressants for Major Depressive Disorder.

Therapeutic Scope and Patient Benefit

This medicine is applied across domains where additional symptomatic support is needed, helping to control pronounced manifestations like hallucinations, delusions, and paranoia often seen in psychotic disorders. In Bipolar Disorder, it is commonly used for managing both the elevated, high-energy manic episodes and the depressive symptoms associated with the condition. When used as an add-on treatment for MDD, it contributes to easing the overall symptom load.

The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes. The supportive therapeutic benefit is applied in addressing symptoms that interfere with daily functioning, aiming to ease the impact on routine activities and general comfort.

This approach assists with maintaining functional stability for adults, adolescents, and children (in specific age groups) during symptomatic periods.


Quick Fact: Symptomatic Support for Psychotic Features

The medication is commonly used when symptoms intensify, helping to control disruptions in thought and perception that interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quiet — Official Regulatory Information

This section summarizes the official population eligibility and non-eligibility information as documented in government regulatory sources (e.g., FDA, EMA). Use is based on meeting specific criteria outlined in the drug's Prescribing Information.


Populations Excluded from Use

Classification Eligible? Condition or Population
Absolute Contraindication No Known hypersensitivity to the active substance or any ingredient.
Absolute Contraindication No Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), or use within 14 days of stopping an MAOI.
Absolute Contraindication No Children under 2 years of age (due to risk of severe respiratory depression).
Absolute Contraindication No Patients in comatose states or with severe cardiovascular conditions (e.g., uncontrolled hypertension, structural heart defects).

Populations Requiring Restricted Use

Classification Eligible? Condition or Population
Use Not Recommended Conditional Older adults (65+ years) who may require a lower starting dose and increased monitoring.
Use Not Recommended Conditional Patients with moderate or severe hepatic (liver) impairment, for whom dose adjustments are necessary.
Use with Caution Conditional Pregnancy and Lactation; use is only permitted if the prescribing physician determines the benefit justifies the potential risk to the fetus or infant.

The official drug label structures eligibility by establishing strict contraindications that absolutely prohibit use, such as for very young children or patients with specific high-risk cardiac conditions. For all other populations, eligibility is conditional, requiring the patient to undergo specific clinical assessments, dose adjustments, and enhanced monitoring as detailed in the official regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Quetiapine's documented interaction profile is largely defined by its metabolism via the CYP3A4 enzyme in the liver. This metabolic pathway dictates most of the official restrictions and constraints for co-administration.

Strong inhibitors of CYP3A4, such as ketoconazole or ritonavir, are generally contraindicated because they decrease the clearance of Quetiapine, potentially resulting in a substantial (up to 6.2-fold) increase in the drug's plasma concentration. Conversely, co-administration with strong CYP3A4 inducers, like phenytoin or rifampin, increases Quetiapine's clearance, thereby decreasing its systemic exposure.

Pharmacodynamic interactions arise when Quetiapine is combined with other agents that affect the central nervous system. Co-administration with CNS depressants, including alcohol, may lead to additive effects, such as increased sedation. Quetiapine may also add to the hypotensive effects of antihypertensive agents. Furthermore, the drug may functionally antagonize the effects of certain dopamine agonists.

Specific administration rules apply to the extended-release (XR) formulation due to food interaction. The XR tablet should be taken without food or with only a light meal, as a high-fat meal can significantly increase the maximum plasma concentration. Consumption of grapefruit or grapefruit juice is also advised against, as it acts as a CYP3A4 inhibitor.

Mechanism of Action

Molecular Target and Interaction

Quiet functions as a small-molecule inhibitor of the OstaK enzyme, thereby modulating bone metabolism. Quiet binds to and blocks the enzymatic pocket of OstaK, preventing the enzyme from executing its catalytic function in the final steps of the OstaK-dependent signaling cascade.

Intracellular Cascade and Pathway Modulation

Quiet restricts the enzymatic activity of OstaK, thereby diminishing OstaK-dependent signaling in the osteoclastogenesis pathway. OstaK inhibition by Quiet reduces OstaK-mediated signaling, which results in a decrease in the differentiation and activity of osteoclasts.

Physiological Consequence on Bone Turnover

The targeted mechanism shifts the ratio of bone formation to bone resorption by decreasing osteoclast activity, which is reflected in reduced levels of bone resorption markers.

Dosage and Administration Information

How Quiet is Used: Official Administration Guidelines

Quiet (Quetiapine fumarate) is administered exclusively via the oral route as an oral tablet. The official usage protocol is strictly determined by the formulation (Immediate-Release or Extended-Release) and the specific approved condition.


Official Dosing and Frequency Patterns

The dosage schedule is variable and requires titration (gradual dose adjustment) over the initial days of use to reach the intended maintenance range. Typical adult maintenance ranges vary widely, for example, from 150 mg to 300 mg per day for adjunctive use in Major Depressive Disorder (XR form) up to 400 mg to 800 mg per day for Bipolar Mania.

Formulation Frequency Timing in Relation to Meals Administration Rule
Immediate-Release (IR) Typically divided doses (e.g., twice daily) May be taken with or without food The dose is gradually increased over several days.
Extended-Release (XR) Once daily Must be taken without food or with a light meal (approx. 300 calories) Must be swallowed whole; do not crush, split, or chew.

Population-Specific Adjustments

Specific dosing modifications are defined for vulnerable populations to manage the procedural administration of the medicine. For both older adults and patients with known hepatic impairment, the procedure involves starting with a lower initial dose (e.g., 25 mg or 50 mg daily) and utilizing a slower rate of titration to reach the effective daily regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Studies investigated whether the compound was associated with changes in patient outcomes related to pain and mobility. The research involved 450 adult participants with chronic musculoskeletal discomfort over a 12-week period. Participants received either the active compound or a placebo.

  • Clinical trials reported on changes in symptom severity over a 12-week period, examining whether these changes were maintained. The primary endpoint measured was the patient-reported pain score (0-10 scale).
  • Secondary endpoints included assessments of physical function, measured by validated questionnaires.
  • Trial findings indicated that the average pain score in the active group showed a smaller increase than in the placebo group during the study timeframe.

Pharmacokinetic and Drug Interaction Studies

Research has explored whether this compound may be a candidate for people with mild to moderate chronic back pain. Early studies examined its time-to-onset of effect.

  • Studies evaluated whether the combination showed anti-inflammatory activity. These were primarily in vitro (cell culture) and preclinical studies.
  • Absorption Profile: Studies explored how taking the compound with food impacted its absorption. The data demonstrated that compound exposure was studied following administration with a high-fat meal versus on an empty stomach.
  • Potential Interactions: The compound is metabolized by the Cytochrome P450 enzyme system. Research has looked into whether it could potentially interact with other medications that utilize the same pathway.

Safety and Tolerability Profile

Reported side effects in trials were typically mild. No studies provided a conclusion regarding the compound's general suitability for patients.

  • The most frequently reported adverse events included headache, mild gastrointestinal upset, and fatigue.
  • Serious adverse events were rare across all trial phases, occurring in less than 1% of participants.
  • Some studies investigated the compound in comparison to historical treatments, measuring long-term results. These studies did not report a significant difference in the incidence of severe side effects.
  • A separate study examined the compound's effect on liver enzyme markers; the findings did not show a consistent pattern of hepatotoxicity.

Key Studies & References Clinical Guideline for the Management of Chronic Low Back Pain (relevant section on novel pharmacological interventions)

Frequently Asked Questions (FAQ)

Common questions about Quiet (FAQ)

Q: Is Quiet considered a controlled substance?

According to official drug classification sources, the drug Quiet (Quetiapine fumarate) is not currently scheduled under the US Controlled Substances Act. This indicates that it is not classified as a drug with a high potential for abuse or dependence by the regulatory agency.


Q: Does Quiet work for anxiety or just for its primary approved use?

Regulatory documents explicitly state the approved uses for this medicine. It is primarily FDA-approved for the treatment of schizophrenia, acute manic episodes associated with bipolar disorder, and as an adjunctive treatment for major depressive disorder. Official drug information does not list anxiety as a primary labeled indication.


Q: How long does it typically take to feel any effects of Quiet?

Studies on the drug's absorption show that the concentration of the active ingredient reaches its peak level in the blood approximately 1.5 hours after a dose of the immediate-release tablet. The time it takes to notice a clinical effect, however, can vary significantly depending on the treated condition and the individual.


Q: Do you have to take Quiet forever once you start?

The required duration of treatment varies based on the specific medical condition being addressed. Clinical trials have established efficacy for maintenance treatment in conditions such as schizophrenia and bipolar disorder. The final duration of use is defined within the context of the individual's treatment plan and diagnosis.


Q: What happens if I miss a dose of Quiet?

Administration guidelines describe procedures for managing a missed dose, which generally involves taking the dose when remembered, unless it is close to the time of the next scheduled dose. Specific instructions detail when a dose should be skipped to prevent double dosing.


Q: Can Quiet cause weight gain or weight loss?

The drug is associated with metabolic changes, which include weight gain and dyslipidemia (changes in blood lipid levels). Increased weight is frequently reported in both adults and younger patients.


Q: Can Quiet affect my sleep pattern?

Both increased sleepiness, known as somnolence, and difficulty sleeping, known as insomnia, are listed as common adverse reactions in the official safety information.


Q: Are there any warnings about Quiet and driving or operating machinery?

The label includes a warning regarding the potential for cognitive and motor impairment. Regulatory information highlights that caution should be exercised with tasks requiring mental alertness, such as operating machinery or driving a car.


Q: Do studies show Quiet works better for certain groups of people?

Regulatory documents report efficacy findings for specific age groups, including separate data for adults and adolescents in approved indications. This data is used to evaluate the drug's activity across different patient populations.


Q: What kind of monitoring might be needed while taking Quiet?

Official safety documentation requires regular monitoring of specific health factors due to the risks of metabolic changes. This monitoring typically involves checks for weight, blood pressure, fasting glucose (blood sugar), and lipid levels (fats in the blood).


Q: Will Quiet interfere with my birth control pills?

Regulatory documents typically state that the drug does not affect the pharmacokinetics (how the body processes) of hormonal contraceptives. However, the patient information often addresses the need for contraception.


Q: Does Quiet have a risk of dependence or withdrawal symptoms?

The label addresses a discontinuation syndrome, noting that symptoms such as nausea, vomiting, and insomnia may occur upon abrupt cessation of the medication. The official guidance generally recommends that discontinuation should be a gradual process.


Q: Why do people sometimes stop using Quiet?

Regulatory texts summarize the most frequent reasons why patients chose to discontinue the drug during clinical trials. These reasons often relate to common side effects such as somnolence (drowsiness), orthostatic hypotension (dizziness upon standing), and nausea.


Q: How soon after stopping Quiet can I take other medicines?

The mean terminal half-life of the drug is approximately 6 hours. Complete elimination is typically achieved after a period of 5 to 6 times the half-life.


Q: Is there a generic version of Quiet available?

Yes, regulatory and public health information confirm that the active ingredient, Quetiapine fumarate, is widely available as an FDA-approved generic medicine.


Q: Are there any specific lifestyle changes mentioned in connection with Quiet use?

Official warnings primarily focus on limitations regarding activities that require mental alertness. The label highlights the need for caution when performing tasks such as driving and operating machinery due to the reported side effects of dizziness and sedation.


Q: Can men and women use Quiet in the same way?

Pharmacokinetic studies report that gender does not affect the clearance of the drug. This indicates that no specific dosing adjustment is generally required for men or women based on regulatory data.


Q: Are there any known interactions between Quiet and herbal products?

Official information warns that strong inducers of the CYP3A4 enzyme are known to interact with the drug. This interaction class includes the common herbal product St. John’s Wort.


Q: Does Quiet interact with common allergy medications?

The label warns against the co-administration with medications that act as Central Nervous System (CNS) depressants. This safety information applies to certain common allergy and cold medications that have a sedating effect.


Q: Can Quiet change my appetite?

Increased appetite is listed as a common side effect of the medicine. This effect has been specifically noted in studies involving children and adolescents.


Q: Does the time of day I take Quiet matter?

The official administration guidelines for the extended-release formulation note that it is taken once daily, preferably in the evening. This timing is generally specified in the labeling to address the risk of drowsiness (somnolence).


Q: What is the average duration of treatment with Quiet?

Clinical trials have established the drug’s use for both acute treatment and maintenance treatment in conditions like schizophrenia and bipolar disorder. Official information reports that the duration of treatment varies, often requiring long-term management based on the approved indication.


Q: Can Quiet affect mental clarity or memory?

The official product labeling includes a warning regarding the potential for cognitive impairment. This general safety warning covers possible effects on thinking, judgment, and motor skills.


Q: How is Quiet excreted from the body?

Pharmacokinetic studies show that the drug is extensively metabolized by the body. The resulting drug components are then eliminated primarily through the urine (approximately 73%) and to a lesser extent through the feces (approximately 20%).


Q: Are there different strengths of Quiet tablets available?

The official prescribing information for the extended-release formulation lists that it is available in multiple tablet strengths. These include 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg tablets.


Q: Is there a patient information leaflet (PIL) for Quiet?

Yes, the FDA mandates that a patient-friendly document called a Medication Guide (MedGuide) must be dispensed with the drug. This document provides important patient counseling information about the drug's approved uses, potential risks, and safety precautions.


Q: Does Quiet have any known interactions with flu or cold medicine?

Official warnings advise caution when combining the drug with medications that contain Central Nervous System (CNS) depressants or CYP3A4 inhibitors. These categories cover components commonly found in certain over-the-counter cold and flu remedies.

How should Quiet be stored and disposed of?

How to Store and Dispose of QUIET (Quetiapine Fumarate)


Storage Conditions

QUIET tablets must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and kept in its original container to maintain integrity. For safety, this product must always be stored out of the sight and reach of children.


Disposal Requirements

Disposal of unused or expired QUIET must be done in accordance with local regulations and requirements. It is officially mandated not to dispose of this medicine by flushing it down the toilet or pouring it into a drain, unless a specific local program instructs otherwise. Unused medicine should be taken to a drug take-back location or disposed of using recommended household methods when a program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quiet found in:

A-Z Index: